Tumor rejection by disturbing tumor stroma cell interactions. - Wikidata - awgldk - TriplyDB

Tumor rejection by disturbing tumor stroma cell interactions.

Tumor rejection by disturbing tumor stroma cell interactions.

http://www.wikidata.org/entity/Q42944518

about

The complex and central role of interferon-γ in graft-versus-host disease and graft-versus-tumor activity Inflammation and cancer, the mastocytoma P815 tumor model revisited: triggering of macrophage activation in vivo with pro-tumorigenic consequences Myeloid-derived cells are key targets of tumor immunotherapy Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth.T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies.Adoptively transferred immune T cells eradicate established tumors despite cancer-induced immune suppression.T cells contribute to tumor progression by favoring pro-tumoral properties of intra-tumoral myeloid cells in a mouse model for spontaneous melanoma.Head and neck cancer relapse after chemoradiotherapy correlates with CD163+ macrophages in primary tumour and CD11b+ myeloid cells in recurrences Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccination Targeting tumor-associated macrophages as a novel strategy against breast cancer.Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination Progression of cancer from indolent to aggressive despite antigen retention and increased expression of interferon-gamma inducible genes Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response.IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.Induced sensitization of tumor stroma leads to eradication of established cancer by T cells.Inhibition of methylcholanthrene-induced carcinogenesis by an interferon gamma receptor-dependent foreign body reaction.Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies.Intravital imaging of CD8+ T cell function in cancer.IDO1 is an Integral Mediator of Inflammatory Neovascularization.Cancer vaccine by fusions of dendritic and cancer cells.Cancer immunotherapy by fusions of dendritic cells and tumor cells.Peptide-mediated targeting of cytokines to tumor vasculature: the NGR-hTNF example.Accelerated tumour metastasis due to interferon-γ receptor-mediated dissociation of perivascular cells from blood vessels.Mannan-modified adenovirus encoding VEGFR-2 as a vaccine to induce anti-tumor immunity.Targeting high-grade B cell lymphoma with CD19-specific T cells.Cyclophosphamide treatment induces rejection of established P815 mastocytoma by enhancing CD4 priming and intratumoral infiltration of P1E/H-2K(d) -specific CD8+ T cells.Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages.High-dose chemotherapy augments the efficacy of recombinant adenovirus vaccines and improves the therapeutic outcome.In vitro generation of cytotoxic and regulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cells Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells.Macrophages Reprogrammed In Vitro Towards the M1 Phenotype and Activated with LPS Extend Lifespan of Mice with Ehrlich Ascites Carcinoma M3 Macrophages Stop Division of Tumor Cells In Vitro and Extend Survival of Mice with Ehrlich Ascites Carcinoma Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice.A VEGFR-3 antagonist increases IFN-γ expression on low functioning NK cells in acute myeloid leukemia.Antagonism by Ganoderma lucidum polysaccharides against the suppression by culture supernatants of B16F10 melanoma cells on macrophage.The Dark Side of IFN-γ: Its Role in Promoting Cancer Immunoevasion.Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication.Visualizing the dynamic of adoptively transferred T cells during the rejection of large established tumors.Critical role of the Th1/Tc1 circuit for the generation of tumor-specific CTL during tumor eradication in vivo by Th1-cell therapy.

P2860

Q26851545-87CC5F6B-1786-473D-A24C-80B9CDA03511 Q28193430-CC2172A7-EE37-4E7B-83B0-899186B9F6F5 Q28388246-0CE03510-3327-4353-8EA5-7ED557169C87 Q33502208-6E745D39-BC2C-434A-B677-D85A7A74DA02 Q33530527-90FCA142-17E6-4E90-AEB3-F5233B2A1B7D Q33854515-439B85AC-6315-4C5B-AD7C-BCFFE03D3FED Q33919802-182CCAE8-470D-4CC0-9577-6C4F1CCC2777 Q34354547-B6A0D83C-B77A-4A5E-BF61-9B2FC630B729 Q34691527-C06762FC-A458-44A5-A71E-6BCAC00080C9 Q34759603-9637ACAF-FEE6-4EEC-AF65-067B2AD37906 Q34803221-53F7552D-54F2-4511-B2C1-C4CAC5F6FAF7 Q35012887-310AC76C-8F9C-4551-8AC4-459CF7F3DC20 Q35079913-9A5A45A1-5A27-4867-A065-DD653B46A1CC Q35828752-6FB67DA0-BADE-45F2-AD38-DF0A7DA17CC4 Q35886767-FDB722A5-A1E7-4552-86D0-5B4A3404AA0A Q36228950-8F95C11B-2548-4F69-82CA-5492393A322C Q36369691-52FF3A49-6F00-4DE4-939D-8EAC2BB028BD Q37107843-D0025447-60B4-49D8-8E59-2CB466B50E4C Q37229840-2DF7D447-BCB8-4CD2-BB98-564214C66F51 Q37510171-F57C08E0-97DD-4193-B377-19C917B6AFD4 Q37698219-189EC8B3-C496-4564-9BB7-149097ABE1E0 Q37773276-B029CBAA-D81E-4171-9686-3E71BD203DEB Q38112578-AD767423-533C-4846-8829-A297F3794A9B Q38707139-DCDF4FE4-FC6B-4680-B98C-5E9625CADED9 Q39024097-DF2BD9D1-1A18-4FED-A39A-C35CA41CC7DC Q39026731-103C403F-DCB4-4629-A6A9-569A3C80712C Q39061560-4E9581D6-F5BE-4889-92FE-D213711F5DDA Q39637537-3E653C8D-FC39-4E65-9FFC-AC1ED9BA7993 Q39920459-4FD75C26-E85F-42E4-8C87-EFC0758E50A5 Q39939752-0BF36215-8665-4545-B5EF-A718B162C688 Q40432901-EE769720-AA11-4986-A28E-9B0FC36BCB56 Q41213052-24538003-743E-4AB8-B893-CE25B55ED43F Q42324194-B739A68F-7014-467A-8BDB-840A0D7A6E30 Q43108657-24DA2BCF-2C5D-497D-8104-1B9BCD2E41DF Q45077403-7BC08AC8-9FD9-4866-9C7C-34BE188CC4BA Q45326678-2AC6BA4B-F963-460F-BEB4-5494F1A3B72F Q48337458-FE7F6FC0-801F-47C6-A1A3-30E0CEE1CEAF Q50957786-5487BE4F-96BB-4D4D-AA5F-1DBEB1010CC9 Q50993575-26015FC9-70E0-4FCD-87B3-68BABA01EF48 Q52005100-7B6DB36E-B98A-4D37-9E22-B0B40EA819CF

P2860

Tumor rejection by disturbing tumor stroma cell interactions.

http://www.wikidata.org/entity/Q42944518

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

2001年论文

@zh

2001年论文

@zh-cn

name

Tumor rejection by disturbing tumor stroma cell interactions.

@en

Tumor rejection by disturbing tumor stroma cell interactions.

@nl

type

label

Tumor rejection by disturbing tumor stroma cell interactions.

@en

Tumor rejection by disturbing tumor stroma cell interactions.

@nl

prefLabel

Tumor rejection by disturbing tumor stroma cell interactions.

@en

Tumor rejection by disturbing tumor stroma cell interactions.

@nl

P1433

Q42944518-087127DF-42D6-4E4D-95A2-E175D2BCFF5A

P1476

Q42944518-90EC6767-37EB-474A-9746-1D439F5E05B0

P2093

Q42944518-1193E3B9-2A4A-4693-A5C0-3E84E1F09F1E

Q42944518-7390BFE8-519F-4175-A316-8E8330E566E9

Q42944518-A1005AB1-E3F9-4113-8B31-2C6C983B91DB

Q42944518-DB8D1011-B22F-42B2-80D5-4F948A224553

Q42944518-F321B7FC-B3C8-4861-84B6-AB93F2C825A9

P2860

Q42944518-0C6708FD-C38B-4679-B45B-9E1F50A5BDBD

Q42944518-0E07C1DB-D21E-4905-8875-F1F5F91C5FF3

Q42944518-12A7AF25-D069-45AD-8ECA-DEDF7FE203AE

Q42944518-17C16A20-9016-4E78-95AC-8C6EE171689E

Q42944518-181722FB-8021-49FB-B58C-6539692A3479

Q42944518-235207B7-38B7-42A5-8A60-46E9577D09A6

Q42944518-264F8DEE-ABA3-47D3-B68E-41C91B07E398

Q42944518-2B6F19E2-78BB-49B2-81F1-3E9CE88855A5

Q42944518-2C99C62D-C5A3-4656-B8A9-6D27EFBDC620

Q42944518-2D189AC2-2C3A-469F-92F3-FE3D11B28A66

P304

Q42944518-D3223DCA-1418-4249-AACE-71842D130DD1

P31

Q42944518-BB422026-62FC-4676-91F8-581DFB6FBBA8

P356

Q42944518-380062F4-E436-474A-9400-87FE80CBA58F

P407

Q42944518-518897E7-22F5-41C5-AB02-F318E1F35E28

P433

Q42944518-585466B8-8D1D-40CD-8DFB-B7E119B388B8

P478

Q42944518-BF045705-8A8F-4041-88B0-A6401BF61346

P577

Q42944518-AEC05EEF-349B-4D16-99B6-0EFA633388C5

P5875

Q42944518-4AE75A24-57CF-4F4F-80DC-C51FB769EAFA

P698

Q42944518-59CB667D-54B3-402E-B8DB-45C7FB01ED85

P932

Q42944518-123CDC48-1D8A-4626-9B5F-C8A00A2793F6

P356

JEM.194.11.1549

P1433

Journal of Experimental Medicine

P1476

Tumor rejection by disturbing tumor stroma cell interactions.

@en

P2093

S Ibe

http://www.w3.org/2001/XMLSchema#string

S Preiss

http://www.w3.org/2001/XMLSchema#string

T Blankenstein

http://www.w3.org/2001/XMLSchema#string

T Schüler

http://www.w3.org/2001/XMLSchema#string

Z Qin

http://www.w3.org/2001/XMLSchema#string

P2860

Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer

Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma

Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression.

The origin and function of tumor-associated macrophages.

CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma.

Induction of antigen-specific T cell anergy: An early event in the course of tumor progression

Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo.

Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma

Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer

P304

1549-1559

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.194.11.1549

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

194

http://www.w3.org/2001/XMLSchema#string

P577

2001-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270114398

http://www.w3.org/2001/XMLSchema#string

P698

11733570

http://www.w3.org/2001/XMLSchema#string

P932

2193522

http://www.w3.org/2001/XMLSchema#string